However, it has been reported that IL-22 treatment may increase the risk of hepatocellular carcinoma possibly by the activation of STAT3, which limits its clinical use as a therapeutic agent for NASH (95). Here, IL22 is linked to metabolic dysfunction-associated steatohepatitis.